®
  • Contact
  • Albumin
  • Products
    • Recombumin®
    • Sample page
  • Albumin Applications
    • COVID-19 Knowledge Hub
    • Cell therapy processing
    • Vaccine stabilization
    • Protein & Peptide formulation
    • Medical device coating
    • Veltis Technology
  • About
    • About Albumedix
    • Management
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog

Formulate with Confidence

Albumedix Recombumin® Medical device coating
  • Recombumin®
    • Protein & Peptide formulation
    • Vaccine stabilization
    • Cell therapy processing
    • Medical device coating
    • COVID-19 Knowledge Hub
  • Library
  • Sample request
Enquire about Recombumin® today

Biocompatible medical device coating using recombinant human albumin

Innovation in medical devices continues to create novel treatment options. However, medical device developers are facing challenges in ensuring safe and biocompatible products. Biocompatibility is crucial when using medical devices to ensure they do not elicit an adverse response by the patient.

Due to its natural propensities, albumin is widely utilized in the medical device industry for coating of stents and tubing, for instance in dialysis, to improve their biocompatibility.

One of our valued medical device partners in the UK; Chalice Medical is an example of a customer we are supporting, with prioritized shipments during the COVID-19 outbreak. Read more HERE

Albumin's natural surface coating ability

Albumin has been demonstrated to cover both hydrophobic and hydrophilic surfaces in nearly a single molecule layer. This means that even small amounts of albumin can effectively cover large areas of surface. Using our recombinant human albumin (rAlb) products it has been shown that:

1-2 mg of albumin is sufficient to cover 1 m2 of surface

 

By coating with albumin, a biological interface is created, thereby limiting the exposure of the otherwise incompatible surface to the patient, increasing product safety.

The improved purity and defined nature of our rAlb product Recombumin® consistently produces the same surface coverage. This makes Recombumin especially suited to the medical devices industry as it minimizes the need for elaborate release procedures and product performance monitoring. Additionally, due to its recombinant nature, Recombumin is free of risk with respect to human derived pathogens and viruses, further warranting a safe product.

Learn more about recombinant human albumin for biocompatible surface coating and drug formulation by reading our whitepaper on formulation (Bookshelf).

CONTACT

Albumedix Ltd.
Mabel Street
The Meadows
Nottingham
NG2 3ED, United Kingdom
Tel: +44 115 9553379
info@albumedix.com

 

Albumedix - Dedicated to Better Health

Albumedix is a science-driven, biotechnology company focused on enabling the creation of superior biopharmaceuticals utilizing our albumin-based drug enhancing technologies. We partner with excellence to improve therapies for people with serious diseases. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical companies worldwide. Headquartered in Nottingham, England with ~100 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started 30 years ago.

 

Privacy | Cookies | Patent Portfolio

ALBUMEDIX, the ALBUMEDIX LOGO, DEDICATED TO BETTER HEALTH and marks such as RECOMBUMIN and VELTIS are trademarks of Albumedix. Albumedix© Copyright 2018

FOLLOW US

  • Albumin
  • Products
    • Recombumin®
    • Sample page
  • Albumin Applications
    • COVID-19 Knowledge Hub
    • Cell therapy processing
    • Vaccine stabilization
    • Protein & Peptide formulation
    • Medical device coating
    • Veltis Technology
  • About
    • About Albumedix
    • Management
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog

We use cookies on our website to improve the website and your experience.

Read more